Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment

Gulhane School of Medicine150 enrolled

Overview

The study is designed to answer the following questions: 1. What is the levels of visceral adiposity index and Triglycerides/HDL cholesterol ratio in hypogonadism? 2. What is the effect of testosterone replacement on the visceral adiposity index and Triglycerides/HDL cholesterol ratio?

This is a retrospective design, which is performed by investigating the registrations of patients with hypogonadotrophic hypogonadism between the years 2007-2010.

Study Type

INTERVENTIONAL

Allocation

Purpose

SCREENING

Masking

NONE

Enrollment

150

Conditions

Hypogonadism

Interventions

TestosteroneDRUG

Testosterone 250 mg injection per 3-4 weeks for 6 months

Eligibility

Sex: MALEMin age: 18 YearsMax age: 26 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Men * Congenital hypogonadism * Treatment Naive Exclusion Criteria: * Previous history of androgen replacement * Hypertension * Diabetes mellitus

Locations (1)

Gulhane School of Medicine

Ankara, Turkey (Türkiye)

Outcomes

Primary Outcomes

time to change of visceral adiposity index with testosteron replacement

Time frame: baseline and 6 months

time to change of TG/HDL cholesterol ratio with testosteron replacement

Time frame: baseline and 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.